Bruker has opened the first Preclinical Imaging Centre in Asia, with the Singapore Bioimaging Consortium (SBIC), a research institute that is part of the Agency for Science, Technology and Research (A*STAR).
The new Preclinical Imaging (PCI) Centre, a key collaboration with the SBIC, is located at their premium premises at Biopolis in Singapore. The SBIC-Bruker PCI centre is the first facility of its kind in Asia and only the second in the world to be opened by Bruker.
Like Bruker’s first preclinical imaging centre located in Massachusetts in the United States, the new SBIC-Bruker PCI centre will provide demonstration, training and applications support for Bruker’s expansive preclinical portfolio and multimodal imaging platforms.
Bruker’s own Centre of Excellence is also located in the Biopolis buildings, so other complementary imaging technologies and a whole suite of leading analytical technologies are also available for demonstration just a few minutes away.
Through the new Centre, A*STAR’s research institutions will be able to leverage Bruker’s advanced imaging platforms to boost their research efforts while the company can tap on SBIC’s talent and imaging capabilities.
Besides gaining access to SBIC’s talent and imaging expertise, the SBIC-Bruker PCI Centre will allow Bruker to foster closer collaborations with SBIC’s partners such as those in the clinical and academic community, as well as the pharmaceutical companies with research operations in Singapore.
(From left to right) Mr Lim Chuan Poh, Chairman of A*STAR, A*STAR’s SBIC Executive Director, Prof Patrick J. Cozzone and President of Bruker Biospin’s Preclinical Imaging Division, Dr Wulf-Ingo Jung